Altimmune (NASDAQ:ALT) Given “Buy” Rating at B. Riley

B. Riley reissued their buy rating on shares of Altimmune (NASDAQ:ALT) in a research report report published on Tuesday morning, Benzinga reports. They currently have a $20.00 target price on the stock.

Several other research firms also recently commented on ALT. HC Wainwright restated a buy rating and set a $12.00 price objective on shares of Altimmune in a report on Tuesday, May 14th. Guggenheim lowered Altimmune from a buy rating to a neutral rating in a research note on Monday, April 29th. JMP Securities decreased their price objective on Altimmune from $25.00 to $24.00 and set a market outperform rating for the company in a report on Friday, May 10th. Finally, Piper Sandler reiterated an overweight rating and set a $25.00 target price on shares of Altimmune in a report on Friday, June 21st. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of Moderate Buy and an average target price of $18.80.

Altimmune Stock Up 3.8 %

ALT stock opened at $7.41 on Tuesday. The firm’s fifty day simple moving average is $7.11 and its two-hundred day simple moving average is $8.80. The stock has a market capitalization of $525.37 million, a price-to-earnings ratio of -4.66 and a beta of 0.11. Altimmune has a twelve month low of $2.09 and a twelve month high of $14.84.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.02. Altimmune had a negative return on equity of 46.96% and a negative net margin of 22,645.37%. The firm had revenue of $0.01 million for the quarter. During the same quarter in the previous year, the company posted ($0.40) earnings per share. As a group, equities research analysts expect that Altimmune will post -1.34 EPS for the current year.

Institutional Trading of Altimmune

Several institutional investors and hedge funds have recently bought and sold shares of ALT. Dark Forest Capital Management LP raised its stake in shares of Altimmune by 13.4% during the 3rd quarter. Dark Forest Capital Management LP now owns 230,353 shares of the company’s stock valued at $599,000 after buying an additional 27,210 shares during the last quarter. GSA Capital Partners LLP grew its holdings in Altimmune by 153.1% during the third quarter. GSA Capital Partners LLP now owns 445,868 shares of the company’s stock worth $1,159,000 after acquiring an additional 269,676 shares during the period. WealthPlan Investment Management LLC purchased a new position in Altimmune during the third quarter valued at approximately $31,000. EWG Elevate Inc. lifted its holdings in Altimmune by 50.0% in the fourth quarter. EWG Elevate Inc. now owns 15,000 shares of the company’s stock valued at $169,000 after acquiring an additional 5,000 shares during the period. Finally, Allied Investment Advisors LLC purchased a new stake in Altimmune in the 4th quarter worth approximately $274,000. 78.05% of the stock is currently owned by institutional investors and hedge funds.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.